ArticleRadiation oncology (London, England)2019
Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis.
Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- EANO guideline on the diagnosis and management of meningiomas.Neuro-oncology · 2021Guideline
- Review
- Optimal α/β Ratio for Biologically Effective Dose-Based Prediction of Radiation-Induced Peritumoral Brain Edema in Meningioma.Cancers · 2026Article
- Reply to Corrales-García, E.M.; Delgado-López, P.D. Comment on "Giotta Lucifero et al. Impact of Irradiation on Post-Surgical Residuals of WHO Grade I Meningioma.Journal of clinical medicine · 2025Article
- Comment on Giotta Lucifero et al. Impact of Irradiation on Post-Surgical Residuals of WHO Grade I Meningioma.Journal of clinical medicine · 2025Article
- Radiosurgery for Intracranial Meningiomas: A Review of Anatomical Challenges and an Update on the Evidence.Cancers · 2024Review
- Multiple meningiomas: Epidemiology, management, and outcomes.Neuro-oncology advances · 2023Article
- Surgery for clinoidal meningiomas with cavernous sinus extension: Near-total excision and chiasmopexy.Acta neurochirurgica · 2022Article
- Management of Medial Sphenoid Wing Meningioma Involving the Cavernous Sinus: A Single-Center Series of 105 Cases.Cancers · 2022Article
- Stereotactic radiosurgery with CyberknifeThe Pan African medical journal · 2022Article
- Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM.Radiation oncology (London, England) · 2021Article
- Stroke rate after external fractionated radiotherapy for benign meningioma.Journal of neuro-oncology · 2021Article
- Article
- Correction to: Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis.Radiation oncology (London, England) · 2020Article
- First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments.Radiation oncology (London, England) · 2020Review
- Multimodal therapy of cavernous sinus meningioma: Impact of surgery andNeuro-oncology advancesArticle
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis retrospective German and Italian multicenter analysis aimed to compare the role of normofractionated stereotactic radiotherapy (nFSRT) to CyberKnife-based hypofractionated stereotactic radiotherapy (CK-hFSRT) for skull base meningiomas.
methodsOverall, 341 patients across three centers were treated with either nFSRT or CK-hFSRT for skull base meningioma. Treatment planning was based on computed tomography (CT) and magnetic resonance imaging (MRI) following institutional guidelines. Most nFSRT patients received 33 × 1.8 Gy, and most CK-hFSRT patients received 5 × 5 Gy. The median follow-up time was 36 months (range: 1-232 months).
resultsIn the CK-hFSRT group, the 1-, 3-, and 10-year local control (LC) rates were 99.4, 96.8, and 80.3%, respectively. In the nFSRT group, the 1-, 3-, and 10-year LC rates were 100, 99, and 79.1%, respectively. There were no significant differences in LC rates between the nFSRT and CK-hFSRT groups (p = 0.56, hazard ratio = 0.76, 95% confidence interval, 0.3-1.9). In the CK-hFSRT group, only one case (0.49%) of severe toxicity (CTCAE 4.0 ≥ 3) was observed. In the nFSRT group, three cases (2.1%) of grade III toxicity were observed.
conclusionThis analysis of pooled data from three centers showed excellent LC and low side effect rates for patients treated with CK-hFSRT or nFSRT. The efficacy, safety, and convenience of a shortened treatment period provide a compelling case for the use of CK-hFSRT in patients with moderate size skull base meningioma and provided that OAR constraints are met.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.